HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bernabei, A. Articles by Edmunds, L. H. Search for Related Content PubMed PubMed Citation Articles by Bernabei, A. Articles by Edmunds, L. H., Jr

Ann Thorac Surg 1995;59:149-153
© 1995 The Society of Thoracic Surgeons

Iloprost and Echistatin Protect Platelets During Simulated Extracorporeal Circulation

Division of Cardiothoracic Surgery, Harrison Department of Surgery, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Accepted for publication July 28, 1994.

Temporary, reversible inhibition of platelets during cardiopulmonary bypass is an attractive strategy to protect platelets and normalize postoperative bleeding times. Iloprost, an analogue of prostacyclin, and the disintegrins reversibly inhibit platelets by different mechanisms. We tested the hypothesis that reduced doses of iloprost and either echistatin, a natural disintegrin, or RO43-5054, a peptidomimetic, in combination provide better platelet protection than any drug alone during simulated extracorporeal circulation. Thirty-five recirculation studies using fresh, heparinized human blood in an extracorporeal perfusion circuit that contained a 0.45-m² spiral coil membrane oxygenator were performed. Iloprost, but neither echistatin nor RO43-5054, increased platelet cyclic adenosine monophosphate. Combinations of iloprost and either fibrinogen receptor antagonist at reduced doses submaximally increased platelet cyclic adenosine monophosphate. Platelet adhesion and release of beta-thromboglobulin antigen was completely inhibited by combinations of the two classes of drugs, but only partially inhibited by each drug alone. Combinations of drugs also completely inhibited platelet aggregation to adenosine diphosphate; these platelets retained full sensitivity to adenosine diphosphate after 90 minutes of recirculation when drugs were removed by gel filtration. We conclude that combinations of iloprost and a fibrinogen receptor antagonist at doses that are unlikely to produce clinical side effects completely inhibit platelet activation and preserve platelet function during in vitro extracorporeal circulation.

This article has been cited by other articles:

				Y. Suzuki, R. Malekan, C. W. Hanson III, S. Niewiarowski, L. Sun, A. K. Rao, and L. H. Edmunds Jr PLATELET ANESTHESIA WITH NITRIC OXIDE WITH OR WITHOUT EPTIFIBATIDE DURING CARDIOPULMONARY BYPASS IN BABOONS J. Thorac. Cardiovasc. Surg., May 1, 1999; 117(5): 987 - 993. [Abstract] [Full Text] [PDF]

				A. Weerasinghe and K. M. Taylor The platelet in cardiopulmonary bypass Ann. Thorac. Surg., December 1, 1998; 66(6): 2145 - 2152. [Abstract] [Full Text] [PDF]

				Y. Suzuki, P. Hillyer, S. Miyamoto, S. Niewiarowski, L. Sun, A. K. Rao, S. Hollenbach, and L. H. Edmunds Jr Integrilin prevents prolonged bleeding times after cardiopulmonary bypass Ann. Thorac. Surg., August 1, 1998; 66(2): 373 - 381. [Abstract] [Full Text] [PDF]

				K. Mellgren, G. Mellgren, S. Lundin, A. Wennmalm, and H. Wadenvik Effect of Nitric Oxide Gas on Platelets During Open Heart Operations Ann. Thorac. Surg., May 1, 1998; 65(5): 1335 - 1341. [Abstract] [Full Text] [PDF]

				T. B. Spanier, M. C. Oz, O. P. Minanov, R. Simantov, W. Kisiel, D. M. Stern, E. A. Rose, and A. M. Schmidt Heparinless cardiopulmonary bypass with active-site blocked factorIXa: A preliminary study on the dog J. Thorac. Cardiovasc. Surg., May 1, 1998; 115(5): 1179 - 1188. [Abstract] [Full Text] [PDF]

				O. Shigeta, H. Kojima, T. Jikuya, Y. Terada, N. Atsumi, Y. Sakakibara, T. Nagasawa, and T. Mitsui Aprotinin Inhibits Plasmin-Induced Platelet Activation During Cardiopulmonary Bypass Circulation, July 15, 1997; 96(2): 569 - 574. [Abstract] [Full Text]

				Y. Hiramatsu, N. Gikakis, H. L. Anderson III, J. H. Gorman III, C. Marcinkiewicz, R. J. Gould, S. Niewiarowski, and L. H. Edmunds Jr. TIROFIBAN PROVIDES ""PLATELET ANESTHESIA"" DURING CARDIOPULMONARY BYPASS IN BABOONS J. Thorac. Cardiovasc. Surg., January 1, 1997; 113(1): 182 - 193. [Abstract] [Full Text]

				K. Mellgren, L. G. Friberg, G. Mellgren, T. Hedner, A. Wennmalm, and H. Wadenvik Nitric Oxide in the Oxygenator Sweep Gas Reduces Platelet Activation During Experimental Perfusion Ann. Thorac. Surg., April 1, 1996; 61(4): 1194 - 1198. [Abstract] [Full Text]